Results 31 to 40 of about 471 (127)

β-Lactam/β-Lactamase Inhibitor Combinations in Sepsis-Associated Acute Kidney Injury and Renal Replacement Therapy [PDF]

open access: yesAntibiotics
Sepsis-associated acute kidney injury (SA-AKI) often requires renal replacement therapy (RRT), which markedly alters antimicrobial pharmacokinetics (PK) and pharmacodynamics (PD). Novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations broaden options
Antonio Lacquaniti   +10 more
doaj   +2 more sources

Carbapenemases in Gram-Negative Bacilli: Classification, Detection, Therapeutic Options, and Resistance to Novel Antimicrobials [PDF]

open access: yesAntibiotics
Carbapenem-resistant Gram-negative bacilli (CR-GNB), particularly Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, remain a major clinical challenge and serious threat to modern medicine, with carbapenemase production representing a
Silvana Vulpie   +7 more
doaj   +2 more sources

Re: ‘In vitro activity of cefepime-enmetazobactam on carbapenem-resistant gram negatives’ by Bonnin et al.

open access: yesClinical Microbiology and Infection
Comment on : Bonnin RA, Jeannot K, Santerre Henriksen A, Quevedo J, Dortet L. In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives. Clin Microbiol Infect. 2025 Feb;31(2):240-249. doi: 10.1016/j.cmi.2024.09.031.
Christophe, Le Terrier   +3 more
openaire   +3 more sources

Revitalizing cephalosporins: The promise of β-lactamase inhibitor combinations

open access: yesGMS Hygiene and Infection Control
This review explore the rise of multidrug-resistant (MDR) Gram-negative bacteria, highlighting β-lactamase inhibitor combinations as crucial therapeutic options.
Marzooka, Kazi-Chishti   +4 more
doaj   +2 more sources

Diagnostic algorithm for the detection of carbapenemases and extended-spectrum β-lactamases in carbapenem-resistant Pseudomonas aeruginosa [PDF]

open access: yesMicrobiology Spectrum
Pseudomonas aeruginosa can acquire carbapenem resistance through various mechanisms, including genomic mutations leading to the overexpression of efflux pumps, intrinsic AmpC-β-lactamase, and/or reduced permeability, and/or through the acquisition of ...
Stefano Mancini   +10 more
doaj   +2 more sources

β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development

open access: yesPathogens
Antimicrobial resistance remains a public health problem of global concern with a great health and financial burden. Its recognition as a threat by political leadership has boosted the research and development of new antibiotics and particularly novel ...
Angeliki Katsarou   +4 more
doaj   +2 more sources

In vitro activity of Cefepime/Enmetazobactam and Cefepime/Zidebactam against OXA-48-producing Klebsiella pneumoniae clinical strains.

open access: yesThe new microbiologica
In this study, we evaluated the in vitro antibacterial activity of cefepime/enmetazobactam and cefepime/zidebactam against well-characterized OXA-48-like producing Klebsiella pneumoniae clinical strains. Genomic analysis revealed that all strains carried class D carbapenemase including blaOXA-48 and blaOXA-181 as well as different ESBL genes.
Bulfoni M.   +4 more
core   +6 more sources

Cefepime-enmetazobactam for complicated urinary tract infections: Redefining ESBL therapy. [PDF]

open access: yesIndian J Med Res
Complicated urinary tract infections (UTIs) caused by extended-spectrum β-lactamase ( ESBL )- and AmpC β-lactamase-producing Enterobacterales are increasing in India, driving carbapenem use.
Chandra P.
europepmc   +4 more sources

Bicyclic Boronate β‐Lactamase Inhibitors: The Present Hope against Deadly Bacterial Pathogens

open access: yesAdvanced Therapeutics, Volume 4, Issue 5, May 2021., 2021
This article highlights the therapeutic potential of recently developed bicyclic boronate inhibitors, such as taniborbactam (VNRX‐5133), VNRX‐7145, and QPX‐7728, for restoring the efficacy of β‐lactam antibiotics against multi‐drug resistant bacteria having distinct resistance mechanisms.
Emilio Lence   +1 more
wiley   +1 more source

Home - About - Disclaimer - Privacy